| A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors (NCT05830045) | Qilu Pharmaceutical Co., Ltd. | 2023-05-19 |
| Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma (NCT05823246) | Qilu Pharmaceutical Co., Ltd. | 2023-04-24 |
| A Study of Olanzapine in Patients With Acute Agitation (NCT05803642) | Qilu Pharmaceutical Co., Ltd. | 2023-03-28 |
| A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 (NCT05758519) | Qilu Pharmaceutical Co., Ltd. | 2023-03-07 |
| A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer (NCT05690945) | Qilu Pharmaceutical Co., Ltd. | 2023-02-15 |
| A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (NCT05703204) | Qilu Pharmaceutical Co., Ltd. | 2023-02-01 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19 (NCT05689203) | Qilu Pharmaceutical Co., Ltd. | 2022-12-30 |
| Lifitegrast Eye Drops in Healthy Subjects：Phase I Study (NCT07040826) | Qilu Pharmaceutical Co., Ltd. | 2022-12-06 |
| Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (NCT05554913) | Qilu Pharmaceutical Co., Ltd. | 2022-11-08 |
| To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation (NCT05555212) | Qilu Pharmaceutical Co., Ltd. | 2022-10-25 |
| QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (NCT05446883) | Qilu Pharmaceutical Co., Ltd. | 2022-09-23 |
| Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations. (NCT05488821) | Qilu Pharmaceutical Co., Ltd. | 2022-06-14 |
| A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer (NCT05329025) | Qilu Pharmaceutical Co., Ltd. | 2022-06-01 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma (NCT05576272) | Qilu Pharmaceutical Co., Ltd. | 2022-05-19 |
| Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer (NCT05309629) | Qilu Pharmaceutical Co., Ltd. | 2022-04-18 |
| A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) (NCT05262413) | Qilu Pharmaceutical Co., Ltd. | 2022-02-28 |
| A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer (NCT05557565) | Qilu Pharmaceutical Co., Ltd. | 2021-12-21 |
| QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors (NCT05108779) | Qilu Pharmaceutical Co., Ltd. | 2021-11-09 |
| Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT05801107) | Qilu Pharmaceutical Co., Ltd. | 2021-10-25 |
| CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (NCT05052567) | Qilu Pharmaceutical Co., Ltd. | 2021-10-21 |
| A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors (NCT05150405) | Qilu Pharmaceutical Co., Ltd. | 2021-10-19 |
| Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections (NCT05060419) | Qilu Pharmaceutical Co., Ltd. | 2021-10-08 |
| A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma (NCT05603039) | Qilu Pharmaceutical Co., Ltd. | 2021-07-01 |
| Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers (NCT06254235) | Qilu Pharmaceutical Co., Ltd. | 2021-06-16 |
| A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies (NCT04954456) | Qilu Pharmaceutical Co., Ltd. | 2021-06-02 |
| Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers (NCT05860530) | Qilu Pharmaceutical Co., Ltd. | 2021-05-10 |
| Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer (NCT04859751) | Qilu Pharmaceutical Co., Ltd. | 2021-03-23 |
| Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (NCT05851027) | Qilu Pharmaceutical Co., Ltd. | 2021-01-15 |
| A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors (NCT05171790) | Qilu Pharmaceutical Co., Ltd. | 2021-01-11 |
| Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. (NCT04629846) | Qilu Pharmaceutical Co., Ltd. | 2020-11-23 |
| A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects (NCT04651036) | Qilu Pharmaceutical Co., Ltd. | 2020-11-06 |
| Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study (NCT06742216) | Qilu Pharmaceutical Co., Ltd. | 2020-11-03 |
| Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD) (NCT05058105) | Qilu Pharmaceutical Co., Ltd. | 2020-10-08 |
| QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer (NCT04864782) | Qilu Pharmaceutical Co., Ltd. | 2020-09-23 |
| A Phase I Study of QL1604 for Advanced Solid Tumors (NCT05801094) | Qilu Pharmaceutical Co., Ltd. | 2020-07-20 |
| QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors (NCT04326829) | Qilu Pharmaceutical Co., Ltd. | 2020-07-08 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD/MAD) (NCT05055687) | Qilu Pharmaceutical Co., Ltd. | 2020-07-05 |
| A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer. (NCT04435652) | Qilu Pharmaceutical Co., Ltd. | 2020-07-01 |
| A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer (NCT05629949) | Qilu Pharmaceutical Co., Ltd. | 2020-04-29 |
| Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers (NCT05716126) | Qilu Pharmaceutical Co., Ltd. | 2020-04-15 |
| A Study of QL1706 in Subjects With Advanced Malignant Tumor (NCT04296994) | Qilu Pharmaceutical Co., Ltd. | 2020-03-31 |
| QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety (NCT04233151) | Qilu Pharmaceutical Co., Ltd. | 2020-01-20 |
| Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous FL058 Administered in Healthy Subjects(SAD) (NCT05058118) | Qilu Pharmaceutical Co., Ltd. | 2019-12-08 |
| Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults (NCT04213105) | Qilu Pharmaceutical Co., Ltd. | 2019-10-31 |
| Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males. (NCT04234594) | Qilu Pharmaceutical Co., Ltd. | 2019-10-28 |
| Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia (NCT05621330) | Qilu Pharmaceutical Co., Ltd. | 2019-10-18 |
| A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) (NCT05345236) | Qilu Pharmaceutical Co., Ltd. | 2019-08-19 |
| An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b (NCT04157699) | Qilu Pharmaceutical Co., Ltd. | 2019-07-26 |
| An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy (NCT04157257) | Qilu Pharmaceutical Co., Ltd. | 2019-07-26 |
| Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT04632758) | Qilu Pharmaceutical Co., Ltd. | 2019-06-01 |
| A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors (NCT05649761) | Qilu Pharmaceutical Co., Ltd. | 2019-05-29 |
| To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors (NCT04550949) | Qilu Pharmaceutical Co., Ltd. | 2019-04-26 |
| A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer (NCT04641754) | Qilu Pharmaceutical Co., Ltd. | 2019-03-07 |
| Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fasted Healthy Volunteers (NCT05528198) | Qilu Pharmaceutical Co., Ltd. | 2018-12-28 |
| Bioequivalence Study of Montelukast Sodium Oral Thin Film and Chewable Tablet in Fed Healthy Volunteers (NCT05531994) | Qilu Pharmaceutical Co., Ltd. | 2018-11-27 |
| Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment (NCT05149924) | Qilu Pharmaceutical Co., Ltd. | 2018-10-31 |
| A Study to Investigate the Safety, Efficacy and PK of Multiple Doses of QL-007 in Chronic Hepatitis B Patients in CHINA (NCT03770624) | Qilu Pharmaceutical Co., Ltd. | 2018-10-16 |
| Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults (NCT03651947) | Qilu Pharmaceutical Co., Ltd. | 2018-08-20 |
| Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR (NCT03381430) | Qilu Pharmaceutical Co., Ltd. | 2018-06-01 |
| A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition (NCT03435666) | Qilu Pharmaceutical Co., Ltd. | 2018-05-01 |
| A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects (NCT03557580) | Qilu Pharmaceutical Co., Ltd. | 2018-04-17 |
| Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD (NCT03312283) | Qilu Pharmaceutical Co., Ltd. | 2017-12-20 |
| Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance (NCT03267654) | Qilu Pharmaceutical Co., Ltd. | 2017-10-12 |
| A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients (NCT03389815) | Qilu Pharmaceutical Co., Ltd. | 2017-09-14 |